1-3 of 3
Vincent Ribrag
Close
Sort by
Journal Articles

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Clinical Trials & Observations
Aaron T. Gerds, Claire N. Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Maria Vannucchi, Rami S Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, MD, Huijing Jiang, Jeanne M Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti
Journal: Blood Advances
Blood Adv bloodadvances.2024012939.
https://doi.org/10.1182/bloodadvances.2024012939
Published: 2024
Includes: Supplemental data
Journal Articles

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Clinical Trials & Observations
Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, Rene-Olivier Casasnovas, François Lemonnier, Gian Matteo Pica, Roch Houot, Loic Ysebaert, Hervé Tilly, Jean-Claude Eisenmann, Steven Le Gouill, Vincent Ribrag, Pascal Godmer, Sylvie Glaisner, Guillaume Cartron, Luc Xerri, Gilles André Salles, Thierry Fest, Franck Morschhauser
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3217–3223.
https://doi.org/10.1182/bloodadvances.2020001955
Published: 2020
Includes: Supplemental data
Journal Articles

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Clinical Trials & Observations
Philippe Armand, John Kuruvilla, Jean-Marie Michot, Vincent Ribrag, Pier Luigi Zinzani, Ying Zhu, Patricia Marinello, Akash Nahar, Craig H. Moskowitz
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2617–2622.
https://doi.org/10.1182/bloodadvances.2019001367
Published: 2020
Includes: Supplemental data